References
- Christiansen C, Christensen M S., Hagen C, Stocklund K-E, Transbøl I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. Acta Obstet Gynecol Scand 1981; 60: 407
- Christiansen C, Christensen M S., McNair P, Hagen C, Stocklund K-E, Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273
- Christiansen C, Christensen M S., Rødbro P, Hagen C, Transbel I. Effect of 1,25-dihydroxy-vitamin D3 in itelf or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981; 11: 305
- Christiansen C, Christensen M S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; i: 459
- Christiansen C, Mazess R B., Transbøl I, Jensen G F. Factors in response to treatment of early postmenopausal bone loss. Calcif Tissue Int 1981; 33: 575
- Hagen C, Christensen M S., Christiansen C, Stocklund K-E, Transbøl I. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period. Acta Obstet Gynecol Scand 1982; 61: 237
- Hagen C, Christiansen C, Christensen M S., Transbøl I. Long-term effect of oestrogen in combination with gestagen on plasma prolactin and FSH levels in postmenopausal women. Acta Endocrinol 1982; 100: 486
- Transbøl I, Christensen M S., Jensen G F., Christiansen C, McNair P. Thiazide for the postponement of postmenopausal bone loss. Metabolism 1981; 31: 383